dr. camidge on inhibiting initial activating egfr mutations and the t790m resistance mutation
Published 10 years ago • 246 plays • Length 0:58Download video MP4
Download video MP3
Similar videos
-
1:52
dr. camidge on optimal therapy in egfr nsclc
-
5:29
osimertinib for the t790m resistance mutation
-
3:59
osimertinib for egfr t790m resistance mutations in nsclc
-
6:14
third-generation egfr inhibitors in nsclc
-
3:48
mechanisms of resistance to upfront egfr-targeted therapy
-
3:24
options for egfr mutation-positive patients with t790m mutation-negative acquired resistance
-
3:02
osimertinib in advanced egfr t790m-mutant nsclc
-
4:25
how to understand egfr t790m mutations | dana-farber cancer institute
-
3:45
azd9291 and rociletinib in t790m-mutant nsclc
-
3:02
osimertinib in advanced egfr t790m-mutant nsclc
-
3:15
does the specific egfr mutation matter when choosing an oral egfr inhibitor?
-
3:37
gracecastuc-022_lung_what is an inherited t790m egfr mutation, and what does it mean?
-
2:15
what is t790m?
-
13:53
emerging options for t790m-positive acquired resistance
-
1:53
resistance to osimertinib in egfr-mutated nsclc
-
3:40
next-generation egfr inhibitors in patients with non-t790m resistance
-
13:06
managing t790-negative egfr-mutated nsclc
-
5:45
osimertinib in t790m-mutant lung cancer
-
3:31
osimertinib plus gefitinib for treatment of egfr-mutated non-small cell lung cancer